This is an observational clinical research study investigating patients with fibrotic interstitial lung disease (fILD), also known as pulmonary fibrosis. It is not known why some patients with fILD clinically deteriorate. This study will investigate whether measuring oxygen levels during sleep or exercise can help identify patients who are at increased risk of clinical deterioration.
This work will build upon the FIBRINOX study, previous clinical research conducted by the Guy's and St Thomas' ILD research team. The FIBRINOX study showed that patients with fILD and normal oxygen saturations at rest, but who desaturate whilst asleep or during exercise, have a significantly increased mortality and greater reduction in quality of life compared to patients who do not desaturate at night or during exercise. The reasons for these differences in mortality and health related quality of life are not known. Data suggests that worsening fILD and the development of pulmonary hypertension, a condition characterised by increased pressure in the pulmonary arteries that is associated with poorer outcomes, may be playing a role. This clinical research study will recruit approximately 160 patients with a tertiary ILD centre diagnosis of fibrotic interstitial lung disease (fILD). Data from routinely performed investigations as part of tertiary ILD assessment will be systematically recorded. Investigations will include lung function tests, echocardiography, blood tests, a 6-minute walk test and overnight oximetry. Participants will also complete several quality-of-life questionnaires. These investigations will be performed at baseline, and again at 12 months, with all tests also repeated at 6 months except for an echocardiogram. After the initial 1 year study period, a 3 year post-recruitment mortality and right heart catheter check will be performed using the participants' medical records. Data will be collected from CT scans and right heart catheters if performed during the study period as part of the participants usual clinical care. This study is designed to establish whether patients with fILD who desaturate during sleep or exercise are more likely to experience functional decline, as well as confirm previous findings of increased mortality and worsening quality of life as demonstrated in the FIBRINOX study. The data generated by this observational study will help generate future hypotheses, research questions and clinical study.
Study Type
OBSERVATIONAL
Enrollment
160
Collection of prospective data all ready available for participant
Guy's & St Thomas' NHS Foundation Trust
London, United Kingdom
Change in 6-minute walk distance
As measured by 6-minute walk test
Time frame: 52 weeks
Mortality
If death occurs during the study period, and the cause of death
Time frame: 52 and 156 weeks
Clinical deterioration
Defined by: decline in forced vital capacity (FVC) \>10% or death
Time frame: 52 weeks
Decline in FVC
Decline in forced vital capacity
Time frame: 52 weeks
Decline in TLCO
Decline in total diffusing capacity of the lungs for carbon monoxide
Time frame: 52 weeks
Pulmonary hypertension
Right heart catheter confirmed pulmonary hypertension
Time frame: 52 and 156 weeks
Change in arterialised capillary blood gas pO2
Arterialised capillary blood gas partial pressure of oxygen
Time frame: 52 weeks
Change in arterialised capillary blood gas oxygen saturations
Arterialised capillary blood gas oxygen saturations
Time frame: 52 weeks
Change in arterialised capillary blood gas pCO2
Arterialised capillary blood gas partial pressure of carbon dioxide
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: 52 weeks
Change in arterialised capillary blood gas HCO3
Arterialised capillary blood gas partial pressure of bicarbonate
Time frame: 52 weeks
Change in arterialised capillary blood gas pH
Arterialised capillary blood gas pH
Time frame: 52 weeks
Time to first acute exacerbation of fILD
The number of days until the participant requires hospital admission for an acute worsening of their respiratory condition, not attributable to other causes
Time frame: 52 weeks
Rate of acute exacerbation of fILD
The number of times the participant requires hospital admission for an acute worsening of their respiratory condition, not attributable to other causes
Time frame: 52 weeks
Change in NT-proBNP/BNP level
Change in NT-proBNP/BNP level from baseline
Time frame: 52 weeks
Change in troponin level
Change in troponin level from baseline
Time frame: 52 weeks
Change in peak TRV
Change in peak tricuspid regurgitation velocity (TRV)
Time frame: 52 weeks
Change in cardiac chamber size/area
Change in cardiac chamber size/area
Time frame: 52 weeks
Change in cardiac chamber area
Change in cardiac chamber area
Time frame: 52 weeks
Change in RV/LV basal diameter area ratio
Change in right ventricle to left ventricle basal diameter area ratio
Time frame: 52 weeks
Change in MPA:AA diameter ratio
Change in main pulmonary artery to ascending aorta diameter ratio
Time frame: 52 weeks
Change in TAPSE/sPAP ratio
Change in tricuspid annular plane systolic excursion to systolic pulmonary artery pressure ratio
Time frame: 52 weeks
Change in European Quality of Life 5-Dimensions 5-Levels (EQ-5D-5L) questionnaire score
Change in score of European Quality of Life 5-Dimensions 5-Levels (EQ-5D-5L) questionnaire
Time frame: 52 weeks
Change in King's Brief Interstitial Lung Disease (KBILD) questionnaire score
Change in score of King's Brief Interstitial Lung Disease (KBILD) questionnaire
Time frame: 52 weeks
Change in Living with Pulmonary Fibrosis (L-IPF) questionnaire score
Change in score of Living with Pulmonary Fibrosis (L-IPF) questionnaire
Time frame: 52 weeks